	US 12,441,791 B2
	Antibodies for treating malignant tumors and uses thereof
Suping Zhang, Guangdong (CN); Thomas James Kipps, Guangdong (CN); Liufeng Wu, Guangdong (CN); and Jianchao Zhang, Guangdong (CN)
Assigned to SHENZHEN UNIVERSITY, Shenzhen (CN)
Filed by SHENZHEN UNIVERSITY, Guangdong (CN)
Filed on Jul. 8, 2021, as Appl. No. 17/369,989.
Application 17/369,989 is a continuation of application No. PCT/CN2019/130493, filed on Dec. 31, 2019.
Claims priority of application No. 201910015048.2 (CN), filed on Jan. 8, 2019.
Prior Publication US 2021/0380688 A1, Dec. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); G01N 33/68 (2006.01)

CPC C07K 16/2803 (2013.01) [C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); G01N 33/68 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2319/03 (2013.01); G01N 2333/70503 (2013.01)]

18 Claims

1. An anti-ROR2 antibody or antigen-binding fragment, comprising:

a light chain variable domain and/or a heavy chain variable domain,

wherein the light chain variable domain comprises a CDR L1 as set forth in SEQ ID NO: 1, a CDR L2 as set forth in SEQ ID NO: 2, and a CDR L3 as set forth in SEQ ID NO: 3, and wherein the heavy chain variable domain comprises a CDR H1 as set forth in SEQ ID NO: 4, a CDR H2 as set forth in SEQ ID NO: 5, and a CDR H3 as set forth in SEQ ID NO: 6;

wherein an epitope of the antibody or antigen-binding fragment is located within a Kringle domain of the extracellular region of ROR2.